Grantham Mayo Van Otterloo & Co. LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Grantham Mayo Van Otterloo & Co. LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 61,474 shares of the biopharmaceutical company’s stock after selling 3,809 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Regeneron Pharmaceuticals were worth $34,565,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of REGN. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $31,000. Caitlin John LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. Traub Capital Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $38,000. Finally, E Fund Management Hong Kong Co. Ltd. grew its stake in Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,274 shares of company stock valued at $4,142,738 over the last three months. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $759.82 on Friday. The company has a market capitalization of $80.33 billion, a PE ratio of 18.28, a P/E/G ratio of 2.04 and a beta of 0.41. The company has a 50-day simple moving average of $770.81 and a two-hundred day simple moving average of $688.75. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the business earned $12.07 EPS. The company’s revenue was up 2.5% compared to the same quarter last year. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Wells Fargo & Company increased their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Scotiabank lifted their price objective on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a report on Monday, November 24th. Finally, Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $802.27.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.